Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
+0.53 (0.62%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 85.20 - 86.02
52 week 81.28 - 123.37
Open 85.82
Vol / Avg. 6.13M/10.17M
Mkt cap 115.01B
P/E 7.34
Div/yield 0.47/2.19
EPS 11.69
Shares 1.33B
Beta 1.07
Inst. own 82%
Jul 26, 2016
Q2 2016 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 14, 2016
Gilead Sciences Inc at William Blair Growth Stock Conference - 9:10AM EDT - Add to calendar
Jun 10, 2016
Gilead Sciences Inc at Jefferies Healthcare Conference - 10:30AM EDT - Add to calendar
Jun 8, 2016
Gilead Sciences Inc at Goldman Sachs Global Healthcare Conference - 2:20PM EDT - Add to calendar
May 23, 2016
Gilead Sciences Inc at UBS Global Healthcare Conference - Webcast
May 11, 2016
Gilead Sciences Inc Annual Shareholders Meeting - Webcast
May 10, 2016
Gilead Sciences Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Gilead Sciences Inc Annual Shareholders Meeting (Estimated)
Apr 28, 2016
Q1 2016 Gilead Sciences Inc Earnings Call - Webcast
Apr 28, 2016
Q1 2016 Gilead Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 45.77% 55.47%
Operating margin 59.67% 68.00%
EBITD margin - 71.14%
Return on average assets 28.76% 41.92%
Return on average equity 89.59% 106.64%
Employees 8,000 -
CDP Score - -


United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Kevin B. Young CBE Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Kathleen Watson Executive Vice President - Human Resources
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Martin Silverstein M.D. Executive Vice President - Strategy
Age: 48
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Kevin E. Lofton Independent Director
Age: 61
Bio & Compensation  - Reuters